Drugs / Anti-GARP Chimeric Antigen Receptor-T Cells
Anti-GARP Chimeric Antigen Receptor-T Cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06964737 | May 2025 → May 2027 expected | grade II glioma, grade III glioma | Ohio State University Comprehensive Cancer Center | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Anti-GARP Chimeric Antigen Receptor-T Cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06964737 ↗ |
| Modality | Cell therapy | “anti-GARP chimeric antigen receptor-expressing T cell (CAR-T) modality” PMID 40873341 ↗ Dec 2025 |
| Route | Other | “Given intracavitary” NCT06964737 ↗ |